KL

If you carry APOE4, the most common genetic risk factor for Alzheimer's disease, there is a second gene that may meaningfully change your odds. A specific version of the KL (Klotho) gene, called KL-VS, appears to lower the risk of Alzheimer's and reduce the buildup of brain proteins linked to the disease, with the protective effect strongest in APOE4 carriers between ages 60 and 80.

Knowing your KL genotype gives you context for everything else you do for your brain. If you have the protective version, you have a tailwind. If you do not, that is information you can use to lean harder on the levers that actually matter for cognitive aging.

What This Gene Does

KL (the gene name for Klotho) sits on chromosome 13 and tells your cells how to build the Klotho protein. Klotho exists in two forms, one anchored to cell surfaces and another that floats freely in the blood. It helps your body manage mineral balance, dampens inflammation, protects blood vessels, and supports signaling in the brain.

The variant most studied in humans is called KL-VS. It is a paired change in the gene that, when inherited from one parent only (a pattern called heterozygosity), tends to raise the amount of Klotho protein your body produces. Inheriting it from both parents does not produce the same benefit and may even carry some risk.

Alzheimer's Disease and Cognitive Health

This is where the evidence is strongest, and where the gene matters most for the reader. KL-VS heterozygosity (the one-copy pattern) has been linked to a lower likelihood of Alzheimer's disease, smaller buildup of amyloid (the protein clumps that mark the disease), and better memory in older adults. The protection appears most pronounced in people who also carry APOE4.

Sources: Belloy et al. 2020; Ali et al. 2021; Driscoll et al. 2021.

What this means for you: if you already know you carry APOE4, adding a KL genotype gives you a more complete picture. A protective KL-VS one-copy result helps explain why some APOE4 carriers age well; a non-carrier result tells you that APOE4 is unopposed in your case and that aggressive attention to cardiovascular, metabolic, and sleep health is even more important.

In a separate study of 243 adults, the actual Klotho protein level (measured in spinal fluid) tracked Alzheimer's status more directly than the KL-VS genotype did, suggesting that the genotype is one input into a broader biology you can also measure through related tests.

Brain Volume and Executive Function

In healthy aging adults, carrying one copy of KL-VS has been linked to larger volume in the prefrontal cortex, the region of the brain responsible for planning and decision-making, and to better performance on tests of executive function. A separate study in 454 cognitively healthy older adults found that KL-VS carriers had lower blood markers of brain inflammation and neurodegeneration than non-carriers.

Longevity: A More Nuanced Picture

Early reports linked KL-VS to longer life, and one meta-analysis grouping multiple studies confirmed an association with exceptional longevity. However, larger and more recent population studies have pushed back. In adults studied in the UK Biobank and the Newcastle 85+ Study, KL variants showed no reliable link to living longer. In 2,921 elderly Swedish men followed prospectively, two KL gene changes were not associated with all-cause or cardiovascular death.

The honest read on the evidence is this: KL-VS may help certain people in certain conditions, particularly those carrying other risk genes like APOE4, but it is not a longevity gene at the population level. Treat any single result as a piece of the puzzle, not a destiny.

Kidney Disease and Cardiovascular Outcomes

Klotho biology is tightly tied to the kidneys, where the protein helps regulate phosphate and mineral balance. In 2,185 adults with chronic kidney disease, a specific combination of three KL gene variants predicted a higher risk of death from non-cardiovascular causes. In 632 adults aged 90 and older, carrying the A version of a KL promoter variant (G-395A) was associated with a lower likelihood of frailty.

On the other hand, in the Framingham Offspring Cohort, KL-VS was not associated with calcification in the heart's valves or major blood vessels. Genetic results for cardiovascular outcomes are mixed, so do not expect this test alone to forecast your heart risk. Use it alongside the standard cardiovascular markers, not in place of them.

Depression and Stress Response

In 329 older adults with late-life major depression, KL gene variants influenced how well people responded to SSRIs (a common class of antidepressants). A separate study of 309 veterans found that KL gene differences shaped how the body responds biologically to chronic psychiatric stress, potentially affecting the pace of cellular aging.

How to Make Sense of a Counterintuitive Pattern

You will see two things in the research that seem to disagree. Some studies say KL-VS predicts longevity. Others say it does not. Some link KL to cardiovascular disease, others find no link. Here is the resolution: KL is not a simple 'good gene, bad gene' marker. It is a modifier, meaning its effect depends on what other risks you carry. Its strongest, most reproducible signal is in APOE4 carriers at risk for Alzheimer's. For other outcomes, the effect is smaller, context-dependent, or absent. Read your result accordingly.

Why a Single Test Is All You Need, and Why That Matters

Your KL genotype does not change over your lifetime. You inherited it at conception and you will have the same result whether you test at 35 or 75. That makes this a one-time test, not something to retrace year after year. It also means the value compounds over decades: the earlier you know, the longer you have to act on the result.

The smartest way to use a genetic result like this is to pair it with biomarkers that do change. The brain proteins amyloid and tau (now measurable in blood) shift over time and respond to interventions. Tracking those proteins gives you a moving picture of brain aging that your fixed KL genotype helps you interpret.

What to Do With an Unexpected Result

If you are KL-VS positive and APOE4 negative, you carry two layers of relative protection against Alzheimer's. This is not a free pass, but it is reassuring context for your long-term brain health plan.

If you are KL-VS positive and APOE4 positive, the research suggests your KL variant may partly counterbalance the APOE4 risk. The protection is largest between ages 60 and 80, which is when prevention work matters most. Treat this as a window for aggressive cardiovascular, metabolic, and sleep optimization.

If you are KL-VS negative and APOE4 positive, you do not have this particular brake on amyloid buildup. Consider ordering blood-based Alzheimer's biomarkers (amyloid beta 42/40 and p-tau217) for an actual look at what is happening in your brain right now, and discuss preventive options with a neurologist or preventive medicine specialist who is experienced with APOE4 carriers.

When Results Can Be Misleading

A few things to keep in mind when reading a KL genotype result:

• Genotype is not destiny: carrying KL-VS lowers Alzheimer's risk on average but does not eliminate it. Lifestyle and other risk factors still drive most of your outcome.
• Two copies are not better than one: the one-copy (heterozygous) pattern is the one linked to protection. The two-copy pattern does not deliver the same benefit and may carry different risks.
• Effects are context-specific: the protection is most clearly demonstrated in APOE4 carriers aged 60 to 80. Younger people, non-APOE4 carriers, and adults over 80 may not see the same benefit.
• The gene is not the protein: your KL genotype is fixed, but your actual Klotho protein levels are shaped by age, kidney function, and other factors. The two are related but not interchangeable.